CN1329031C - 一种调血脂药物组合物及其用途 - Google Patents
一种调血脂药物组合物及其用途 Download PDFInfo
- Publication number
- CN1329031C CN1329031C CNB2005100492079A CN200510049207A CN1329031C CN 1329031 C CN1329031 C CN 1329031C CN B2005100492079 A CNB2005100492079 A CN B2005100492079A CN 200510049207 A CN200510049207 A CN 200510049207A CN 1329031 C CN1329031 C CN 1329031C
- Authority
- CN
- China
- Prior art keywords
- blood
- simvastatin
- pantethine
- preparation
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 230000001105 regulatory effect Effects 0.000 title claims description 8
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims abstract description 44
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims abstract description 44
- 229960002855 simvastatin Drugs 0.000 claims abstract description 44
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims abstract description 42
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims abstract description 40
- 235000008975 pantethine Nutrition 0.000 claims abstract description 40
- 239000011581 pantethine Substances 0.000 claims abstract description 40
- 229960000903 pantethine Drugs 0.000 claims abstract description 40
- 210000004369 blood Anatomy 0.000 claims abstract description 31
- 239000008280 blood Substances 0.000 claims abstract description 31
- 238000002360 preparation method Methods 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 20
- 150000002632 lipids Chemical class 0.000 claims abstract description 18
- 229930003935 flavonoid Natural products 0.000 claims abstract description 11
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 11
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 11
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 7
- 239000000654 additive Substances 0.000 claims abstract description 3
- 230000000996 additive effect Effects 0.000 claims abstract description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 28
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 28
- 235000008696 isoflavones Nutrition 0.000 claims description 28
- 244000068988 Glycine max Species 0.000 claims description 26
- 235000010469 Glycine max Nutrition 0.000 claims description 26
- 235000011201 Ginkgo Nutrition 0.000 claims description 14
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 14
- 229930003944 flavone Natural products 0.000 claims description 14
- 150000002213 flavones Chemical class 0.000 claims description 14
- 235000011949 flavones Nutrition 0.000 claims description 14
- -1 2-mercaptoethyl Chemical group 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 244000194101 Ginkgo biloba Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 238000011160 research Methods 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 19
- 102000007330 LDL Lipoproteins Human genes 0.000 description 19
- 238000000034 method Methods 0.000 description 15
- 241000218628 Ginkgo Species 0.000 description 13
- SQGLUEWZRKIEGS-UHFFFAOYSA-N Ginkgetin Natural products C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 SQGLUEWZRKIEGS-UHFFFAOYSA-N 0.000 description 11
- 229930045534 Me ester-Cyclohexaneundecanoic acid Natural products 0.000 description 11
- 108010010234 HDL Lipoproteins Proteins 0.000 description 10
- 102000015779 HDL Lipoproteins Human genes 0.000 description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- AIFCFBUSLAEIBR-UHFFFAOYSA-N ginkgetin Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C(C=1)=CC=C(OC)C=1C1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 AIFCFBUSLAEIBR-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229940103115 simvastatin 20 mg Drugs 0.000 description 4
- 229940096805 simvastatin 5 mg Drugs 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 229940031620 pantethine 500 mg Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108700022737 rat Fat1 Proteins 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- UNLRVSBRNJYNHN-UHFFFAOYSA-N [cyano-(3-phenoxyphenyl)methyl] 2-(4-chlorophenyl)-3-methylbutanoate;dimethoxy-(4-nitrophenoxy)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C=C1.C=1C=C(Cl)C=CC=1C(C(C)C)C(=O)OC(C#N)C(C=1)=CC=CC=1OC1=CC=CC=C1 UNLRVSBRNJYNHN-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BEGBSFPALGFMJI-UHFFFAOYSA-N ethene;sodium Chemical group [Na].C=C BEGBSFPALGFMJI-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- SYKWLIJQEHRDNH-KRPIADGTSA-N glutaryl-coa Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSC(=O)CCCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SYKWLIJQEHRDNH-KRPIADGTSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010030696 low density lipoprotein triglyceride Proteins 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
大豆异黄酮4片中(1400mg) | 银杏总黄酮4片中1400mg) | |
辛伐他汀 | 20mg | 20mg |
泛硫乙胺 | 500mg | 500mg |
大豆异黄酮 | 225mg | - |
银杏黄酮 | - | 225mg |
结晶纤维素 | 120mg | 120mg |
偏硅酸铝酸镁 | - | - |
蔗糖脂肪酸酯 | 140mg | 140mg |
羟丙基纤维素 | 48mg | 48mg |
硬脂酸镁 | 24mg | 24mg |
交联聚维酮 | 48mg | 48mg |
乳糖 | 适量 | 适量 |
大豆异黄酮4包(5g) | 银杏总黄酮4包(5g) | |
辛伐他汀 | 20mg | 20mg |
泛硫乙胺 | 1000mg | 1000mg |
大豆异黄酮 | 300mg | - |
银杏总黄酮 | - | 300mg |
精制蔗糖 | 1600mg | 1600mg |
淀粉 | 1200mg | 1200mg |
聚山梨醇酯80 | 48mg | 48mg |
偏硅酸铝酸镁 | - | - |
硬脂酸镁 | 24mg | 24mg |
乳糖 | 适量 | 适量 |
大豆异黄酮4胶囊中 | 银杏总黄酮4胶囊中 | |
辛伐他汀 | 20mg | 20mg |
泛硫乙胺 | 500mg | 500mg |
大豆异黄酮 | 300 | - |
银杏总黄酮 | - | 300 |
淀粉 | 960mg | 960mg |
聚山梨醇酯80 | 48mg | 48mg |
偏硅酸铝酸镁 | - | - |
硬脂酸镁 | 24mg | 24mg |
乳糖 | 适量 | 适量 |
大豆异黄酮100mL中 | 银杏总黄酮100mL中 | |
辛伐他汀 | 20mg | 20mg |
泛硫乙胺 | 500mg | 500mg |
大豆异黄酮 | 300 | - |
银杏总黄酮 | - | 300 |
D-山梨醇液 | 6g | 6g |
蜂蜜 | 8g | 8g |
乙二胺四乙酸钠 | 20mg | 20mg |
乙醇 | 2mL | 2mL |
硬脂酸聚氧乙烯硬化 | 100mg | 100mg |
蓖麻油60 | ||
苯甲酸钠 | 60mg | 60mg |
香料 | 微量 | 微量 |
蒸馏水 | 适量 | 适量 |
组别 | 血清脂质升高值(mg/dl) | 毒性(U/L) | |||||||
总胆固醇 | 甘油三脂 | 高密度脂蛋白 | 低密度脂蛋白 | 极低密度脂蛋白 | 总胆固醇/高密度脂蛋白 | 丙氨酸氨基转移酶(ALT) | 肌酸激酶 | 天冬氨酸氨基转移酶酶(AST) | |
溶剂 | 209±31 | 61±20 | 12±9 | 180±36 | 21±17 | 2.23±0.72 | 42±9 | 609±150 | 175±35 |
辛伐他汀4mg/kg | 147±25* | 56±18 | 16±12 | 138±23* | 23±13 | 2.23 ±0.59 | 69±21* | 616±83 | 189±24 |
泛硫乙胺60mg/kg | 198±62 | 63±26 | 23±9* | 178±49 | 24±13 | 1.94 ±0.76 | 41±9 | 633±134 | 184±35 |
辛伐他汀3 | 166±73 | 63±29 | 20±13 | 154±62 | 15±14 | 1.99±0.81 | 52±25 | 629±162 | 183±27 |
mg/kg+泛硫乙胺45mg/kg | |||||||||
辛伐他汀3mg/kg+泛硫乙胺45mg/kg+银杏总黄酮30mg/kg | 119±23*# | 49±20*# | 24±11* | 122±29*# | 11±9*# | 2.62±0.83 | 43±7# | 606±183 | 168±28 |
辛他汀3mg/kg+泛硫乙胺45mg/kg+大豆异黄酮30mg/kg | 103±30*## | 41±18*# | 24±7 | 118±20*# | 8±8*# | 1.54±0.31# | 40±9# | 602±133 | 164±30 |
组别(mg/kg) | 血清脂质降低值(mg/dl) | 肝毒性(U/L) | ||||
T-ch | TG | HDL-CH | LDL-CH | ALT | AST | |
溶剂 | 597±127 | 20±10 | 135±26 | 434±110 | 52±13 | 63±19 |
辛伐他汀5mg/kg | 826±110* | 27±9 | 178±34 | 554±97 | 79±12* | 79±21* |
泛硫乙胺30mg/kg | 618±105 | 27±15 | 190±27 | 585±106* | 31±9 | 54±14 |
辛伐他汀2.5mg/kg+泛硫乙胺22.5mg/kg+银杏黄酮2.5mg/kg | 851±124* | 22±13 | 199±31* | 558±85* | 45±19# | 50±18# |
辛伐他汀2.5mg/kg+泛硫乙胺22.5mg/kg+大豆异黄酮2.5mg/kg | 982±97*# | 35±10 | 223±32*# | 713±108*# | 41±17# | 50±10# |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100492079A CN1329031C (zh) | 2005-01-24 | 2005-01-24 | 一种调血脂药物组合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100492079A CN1329031C (zh) | 2005-01-24 | 2005-01-24 | 一种调血脂药物组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1679547A CN1679547A (zh) | 2005-10-12 |
CN1329031C true CN1329031C (zh) | 2007-08-01 |
Family
ID=35066570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100492079A Expired - Fee Related CN1329031C (zh) | 2005-01-24 | 2005-01-24 | 一种调血脂药物组合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1329031C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107213189A (zh) * | 2017-06-02 | 2017-09-29 | 烟台大学 | 抑制pcsk9基因表达的药物组合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1141092A (zh) * | 1994-01-11 | 1997-01-22 | 先进Risc机器有限公司 | 数据存储器和处理器总线 |
CN1489462A (zh) * | 2000-12-14 | 2004-04-14 | 三共株式会社 | 血液脂质改善剂组合物 |
-
2005
- 2005-01-24 CN CNB2005100492079A patent/CN1329031C/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1141092A (zh) * | 1994-01-11 | 1997-01-22 | 先进Risc机器有限公司 | 数据存储器和处理器总线 |
CN1489462A (zh) * | 2000-12-14 | 2004-04-14 | 三共株式会社 | 血液脂质改善剂组合物 |
Non-Patent Citations (1)
Title |
---|
大豆异黄酮对冠心病患者血脂达标率的影响 肖立中等,临床内科杂志,第21卷第6期 2004 * |
Also Published As
Publication number | Publication date |
---|---|
CN1679547A (zh) | 2005-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103945848B (zh) | 被取代的喹唑啉酮的口服即释制剂 | |
Susalit et al. | Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: comparison with Captopril | |
US11337955B2 (en) | Compositions and methods to regulate hormonal cascades in stress disorders | |
US20120269868A1 (en) | Compositions and methods for nutritional supplementation | |
WO2008122190A1 (fr) | Composition comprenant de la l-carnitine ou ses dérivés et son utilisation | |
US7977378B1 (en) | Compositions and methods for enhancing weight-loss by cyclical administration of compounds | |
US9642860B2 (en) | Combinations of corroles and statins | |
CN101014334A (zh) | 丙型肝炎病毒阳性人肝硬化患者用肝癌发生和发展抑制剂 | |
CN1329031C (zh) | 一种调血脂药物组合物及其用途 | |
US20110117070A1 (en) | Compositions and methods for treating headache | |
CN101884643B (zh) | 含有吡格列酮和肝素或低分子肝素的药物组合物的新用途 | |
CN111629784A (zh) | 用于调节总血液胆固醇的天然组合产品和方法 | |
CN1332657C (zh) | 一种含洛伐他汀的组合物及其用途 | |
CN103919765B (zh) | 高车前素在制备儿茶酚药物增效剂中的应用及包含高车前素的药物组合物 | |
US20090214682A1 (en) | Composition and methods for weight loss in a subject | |
CN113271931A (zh) | 氨基甲酸酯β苯乙醇胺类似物增强胞内LDL胆固醇的清除及与他汀类药物联用的新用途 | |
CN101259126A (zh) | 一种治疗高脂血症的组合物及其制备方法 | |
CN1274302C (zh) | 含阿伐他汀的降血脂组合物及其用途 | |
CN104840480B (zh) | 二甲双胍/叶酸/维生素b12药物组合物的新用途 | |
JP2020519576A5 (zh) | ||
KR20020025066A (ko) | HMG-CoA 리덕타제 억제제 및 카르니틴을 포함하는항지질혈성 복합제 | |
CN113133997A (zh) | 一种含小檗碱的药物组合物及其用途 | |
CN102416015A (zh) | 一种含他汀类药物的组合物及其用途 | |
EP2958627A1 (en) | Composition for the treatment of metabolic disorders | |
Yin et al. | Zetia®(Ezetimibe) Drug Monograph |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: XINFU PHARMACEUTICAL IND CO., LTD., HANGZHOU Effective date: 20080215 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080215 Address after: Ling'an Economic Development Zone, Zhejiang Patentee after: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL Co.,Ltd. Address before: Ling'an Economic Development Zone (Qingshan Lake Street), Zhejiang, China Patentee before: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL Co.,Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 311300 Ling'an Economic Development Zone, Zhejiang Patentee after: YIFAN XINFU PHARMACEUTICAL Co.,Ltd. Address before: 311300 Ling'an Economic Development Zone, Zhejiang Patentee before: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20160720 Address after: Hangzhou City, Zhejiang province 311300 Ling'an City Kam South Street No. 9 Gua fan Patentee after: HANGZHOU XINFU SCIENCE & TECHNOLOGY Co.,Ltd. Address before: 311300 Ling'an Economic Development Zone, Zhejiang Patentee before: YIFAN XINFU PHARMACEUTICAL Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070801 Termination date: 20210124 |